Psilocybin with Acceptance and Commitment Therapy (ACT) for the Treatment of Social Anxiety Disorder (SAD)

Social Anxiety Disorder involves intense fear of rejection and social avoidance. While standard treatments exist, many patients do not improve or relapse over 10-12 years. Acceptance and Commitment Therapy, a third-wave cognitive behavioral therapy, shows early promise comparable to Cognitive Behavioral Therapy, the first-line treatment. Combining ACT with Psychedelic-Assisted Psychotherapy may offer an alternative by targeting emotional and behavioral patterns through a biopsychosocial lens. This paper explores the theoretical rationale, practical implementation, and potential obstacles of this novel approach.

Study at a glance

Abstract

Social Anxiety Disorder (SAD) is a debilitating mental health condition characterized by an overwhelming fear and anxiety of social rejection that can lead to chronic patterns of social behavioral avoidance. Despite the existence of traditional efficacious treatments, a significant number of individuals either do not respond to treatment or experience a recurrence of symptoms over extended periods, spanning 10-12 years. Acceptance and Commitment Therapy (ACT), a form of acceptance-based behavioral therapy considered part of the "third wave" of cognitive behavioral therapies, has shown promising results in early studies, comparable to those of Cognitive Behavioral Therapy (CBT) that is considered the first-line treatment for SAD. When combined with Psychedelic-Assisted Psychotherapy (PAP), ACT may offer a viable efficacious alternative. This combination has the potential to improve therapeutic outcomes by addressing the underlying emotional and behavioral patterns that perpetuate SAD through a biopsychosocial approach. This paper examines the theoretical basis, practical considerations, and potential challenges associated with this innovative treatment approach.